RING domain–deficient BRCA1 promotes PARP inhibitor and platinum resistance

Patients with cancers that harbor breast cancer 1 (BRCA1) mutations initially respond well to platinum and poly(ADP-ribose) polymerase inhibitor (PARPi) therapy; however, resistance invariably arises in these patients and is a major clinical problem. The BRCA1(185delAG) allele is a common inherited...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Invest
Egile Nagusiak: Wang, Yifan, Krais, John J., Bernhardy, Andrea J., Nicolas, Emmanuelle, Cai, Kathy Q., Harrell, Maria I., Kim, Hyoung H., George, Erin, Swisher, Elizabeth M., Simpkins, Fiona, Johnson, Neil
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Clinical Investigation 2016
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4966309/
https://ncbi.nlm.nih.gov/pubmed/27454289
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI87033
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak